Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 4 completed trials

    Completion Rate
    100%(4/4)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)

    Phase Distribution

    Phase 2
    1
    25%
    Phase 1
    3
    75%

    Phase Distribution

    3

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution4 total trials
    Phase 1Safety & dosage
    3(75.0%)
    Phase 2Efficacy & side effects
    1(25.0%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    100.0%

    4 of 4 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    4

    all time

    Status Distribution
    Completed(4)

    Detailed Status

    Completed4

    Development Timeline

    Analytics

    Development Status

    Total Trials
    4
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 13 (75.0%)
    Phase 21 (25.0%)

    Trials by Status

    completed4100%

    Recent Activity

    0 active trials
    Showing 4 of 4
    completedphase_1

    Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis

    NCT00111514
    completedphase_1

    Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis

    NCT00111553
    completedphase_1

    Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite

    NCT00121849
    completedphase_2

    Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite

    NCT00121862

    Clinical Trials (4)

    Showing 4 of 4 trials
    NCT00111514Phase 1

    Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis

    Completed
    NCT00111553Phase 1

    Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis

    Completed
    NCT00121849Phase 1

    Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite

    Completed
    NCT00121862Phase 2

    Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite

    Completed

    All 4 trials loaded

    Drug Details

    Intervention Type
    Biological
    Total Trials
    4